MCID: EST002
MIFTS: 45

Estrogen-Receptor Negative Breast Cancer

Categories: Cancer diseases

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer 12 15 17

Classifications:



External Ids:

Disease Ontology 12 DOID:0060076

Summaries for Estrogen-Receptor Negative Breast Cancer

Disease Ontology : 12 A breast cancer that is characterized by the absence of estrogen receptors.

MalaCards based summary : Estrogen-Receptor Negative Breast Cancer is related to bone resorption disease and estrogen-receptor positive breast cancer. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are Signaling by GPCR and ERK Signaling. The drugs Bevacizumab and Methotrexate have been mentioned in the context of this disorder. Affiliated tissues include breast, bone and ovary, and related phenotypes are endocrine/exocrine gland and growth/size/body region

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 271)
# Related Disease Score Top Affiliating Genes
1 bone resorption disease 30.2 IGF1 ESR1 CYP19A1 CTNNB1
2 estrogen-receptor positive breast cancer 29.5 VEGFA SRC PGR GPER1 FOXA1 ESR1
3 peripheral nervous system disease 29.4 VEGFA SRC IGF1 ERBB2 EGFR EGF
4 diabetes mellitus 29.4 VEGFA IGF1 ESR1 EGFR EGF CYP19A1
5 breast cancer 28.8 VEGFA TGFBR2 SRC PGR MIR520C IGF1
6 ovarian cancer 28.7 VEGFA TGFBR2 SRC PGR GPER1 ESR1
7 bartholin's gland adenoma 10.5 PGR ESR1
8 bartholin's gland adenoid cystic carcinoma 10.5 PGR ESR1
9 uterine corpus adenosarcoma 10.5 PGR ESR1
10 bartholin's gland benign neoplasm 10.5 PGR ESR1
11 chronic tympanitis 10.5 PGR ESR1
12 vestibular gland benign neoplasm 10.5 PGR ESR1
13 granulomatous endometritis 10.4 PGR ESR1
14 vulvar syringoma 10.4 PGR ESR1
15 calcifying aponeurotic fibroma 10.4 PGR EGF
16 scirrhous adenocarcinoma 10.4 PGR ERBB2
17 lipid-rich breast carcinoma 10.4 PGR ERBB2
18 lung leiomyoma 10.4 PGR ESR1
19 adult type testicular granulosa cell tumor 10.4 PGR ESR1
20 cervical clear cell adenocarcinoma 10.4 PGR ESR1
21 glassy cell carcinoma of the cervix 10.4 PGR ESR1 ERBB2
22 breast intraductal papillomatosis 10.4 PGR ESR1 ERBB2
23 intraductal papilloma 10.4 PGR ESR1 ERBB2
24 nipple carcinoma 10.4 PGR ESR1 ERBB2
25 ovarian seromucinous carcinoma 10.4 PGR ESR1
26 apocrine adenosis of breast 10.4 PGR ERBB2
27 benign breast adenomyoepithelioma 10.4 ESR1 EGFR
28 breast papillary carcinoma 10.4 PGR ESR1 ERBB2
29 comedo carcinoma 10.4 PGR ESR1 ERBB2
30 breast adenoid cystic carcinoma 10.4 PGR ESR1 ERBB2
31 lipid-rich carcinoma 10.4 PGR ESR1 ERBB2
32 breast osteosarcoma 10.4 PGR ESR1 ERBB2
33 breast neuroendocrine neoplasm 10.4 PGR ESR1 ERBB2
34 subserous uterine fibroid 10.4 PGR CYP19A1
35 basaloid lung carcinoma 10.4 PGR BRCA1
36 intraductal breast benign neoplasm 10.4 PGR ESR1 ERBB2
37 cribriform carcinoma 10.4 PGR ESR1 ERBB2
38 vaginitis 10.4 ESR1 CXCL8 AR
39 retinitis pigmentosa 47 10.4 PGR ESR1 ERBB2
40 adenosarcoma 10.4 PGR ESR1 ERBB2
41 diffuse peritoneal leiomyomatosis 10.4 PGR CYP19A1
42 short syndrome 10.4 PGR ESR1 ERBB2
43 liver leiomyoma 10.4 PGR ESR1
44 endometritis 10.4 PGR ESR1 CXCL8
45 small cell carcinoma 10.4 ERBB2 EGFR AR
46 endocervical adenocarcinoma 10.4 PGR ESR1 ERBB2
47 biliary tract cancer 10.4 TGFBR2 ERBB2 EGFR
48 wolffian duct adenocarcinoma 10.3 ESR1 AR
49 testicular germ cell cancer 10.3 ESR1 CYP1B1 AR
50 ovarian endometrioid stromal sarcoma 10.3 PGR CYP19A1 AR

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:



Diseases related to Estrogen-Receptor Negative Breast Cancer

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.44 AR BRCA1 CTNNB1 CYP19A1 EGF EGFR
2 growth/size/body region MP:0005378 10.43 AR BRCA1 CTNNB1 CYP19A1 EGF EGFR
3 homeostasis/metabolism MP:0005376 10.41 AR BRCA1 CTNNB1 CYP19A1 CYP1B1 EGFR
4 cellular MP:0005384 10.4 AR BRCA1 CTNNB1 CYP19A1 EGFR ERBB2
5 cardiovascular system MP:0005385 10.38 AR BRCA1 CTNNB1 CYP19A1 EGFR ERBB2
6 immune system MP:0005387 10.37 AR BRCA1 CTNNB1 CYP19A1 EGF EGFR
7 integument MP:0010771 10.36 AR BRCA1 CTNNB1 CYP19A1 EGF EGFR
8 hematopoietic system MP:0005397 10.33 AR BRCA1 CTNNB1 CYP19A1 EGFR ESR1
9 digestive/alimentary MP:0005381 10.32 AR BRCA1 CTNNB1 CYP19A1 EGF EGFR
10 embryo MP:0005380 10.27 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
11 neoplasm MP:0002006 10.25 AR BRCA1 CTNNB1 CYP1B1 EGFR ERBB2
12 limbs/digits/tail MP:0005371 10.24 AR BRCA1 CTNNB1 EGFR ERBB2 ESR1
13 muscle MP:0005369 10.23 AR BRCA1 CTNNB1 CYP19A1 EGFR ERBB2
14 nervous system MP:0003631 10.18 AR BRCA1 CTNNB1 CYP19A1 EGFR ERBB2
15 normal MP:0002873 10.15 AR BRCA1 CTNNB1 CYP19A1 EGF EGFR
16 liver/biliary system MP:0005370 10.08 AR CTNNB1 CYP19A1 EGFR ESR1 GPER1
17 reproductive system MP:0005389 9.97 AR BRCA1 CTNNB1 CYP19A1 EGF EGFR
18 renal/urinary system MP:0005367 9.91 AR BRCA1 CTNNB1 CYP19A1 EGFR ESR1
19 pigmentation MP:0001186 9.87 AR BRCA1 CTNNB1 CYP19A1 EGFR SRC
20 respiratory system MP:0005388 9.61 BRCA1 CTNNB1 EGFR ERBB2 ESR1 IGF1
21 skeleton MP:0005390 9.44 AR BRCA1 CTNNB1 CYP19A1 EGFR ERBB2

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 92)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Bevacizumab Approved, Investigational Phase 2 216974-75-3
2
Methotrexate Approved Phase 2 1959-05-2, 59-05-2 126941
3
Medroxyprogesterone acetate Approved, Investigational Phase 2 71-58-9
4
Levoleucovorin Approved, Investigational Phase 2 68538-85-2 149436
5
Progesterone Approved, Vet_approved Phase 2 57-83-0 5994
6
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
7
Vinorelbine Approved, Investigational Phase 2 71486-22-1 60780 44424639
8
Sargramostim Approved, Investigational Phase 2 123774-72-1, 83869-56-1
9
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
10
Melphalan Approved Phase 2 148-82-3 4053 460612
11
Sodium citrate Approved, Investigational Phase 2 68-04-2
12
Busulfan Approved, Investigational Phase 2 55-98-1 2478
13
Aldesleukin Approved Phase 2 110942-02-4, 85898-30-2
14
Thiotepa Approved, Investigational Phase 2 52-24-4 5453
15
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
16
Capecitabine Approved, Investigational Phase 2 154361-50-9 60953
17
Lenograstim Approved, Investigational Phase 2 135968-09-1
18
Letrozole Approved, Investigational Phase 2 112809-51-5 3902
19
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
20
Epirubicin Approved Phase 2 56420-45-2 41867
21
Doxorubicin Approved, Investigational Phase 2 23214-92-8 31703
22
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
23
Dasatinib Approved, Investigational Phase 2 302962-49-8 3062316
24
Anastrozole Approved, Investigational Phase 2 120511-73-1 2187
25
Tamoxifen Approved Phase 2 10540-29-1 2733526
26
Cisplatin Approved Phase 1, Phase 2 15663-27-1 84093 441203 2767
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
28
Citric acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
29
Phenylalanine Approved, Investigational, Nutraceutical Phase 2 63-91-2 6140
30
Saracatinib Investigational Phase 2 379231-04-6
31
Veliparib Investigational Phase 2 912444-00-9 11960529
32
Molgramostim Investigational Phase 2 99283-10-0
33
Entinostat Investigational Phase 2 209783-80-2
34 Antineoplastic Agents, Immunological Phase 2
35 Angiogenesis Inhibitors Phase 2
36 Immunoglobulins Phase 2
37 Immunoglobulins, Intravenous Phase 2
38 Antibodies Phase 2
39 Antibodies, Monoclonal Phase 2
40 Immunologic Factors Phase 2
41 11-hydroxyprogesterone Phase 2
42 Antirheumatic Agents Phase 2
43 Vitamin B9 Phase 2
44 Alkylating Agents Phase 2
45 17 alpha-Hydroxyprogesterone Caproate Phase 2
46 Immunosuppressive Agents Phase 2
47 Folic Acid Antagonists Phase 2
48
Medroxyprogesterone Phase 2 520-85-4 10631
49 Vitamin B Complex Phase 2
50 Folate Phase 2

Interventional clinical trials:

(show all 17)
# Name Status NCT ID Phase Drugs
1 Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer Active, not recruiting NCT01805076 Phase 3
2 Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib Completed NCT00733408 Phase 2 paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
3 MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial Completed NCT00577122 Phase 2 Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
4 A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer Completed NCT00559507 Phase 2 saracatinib
5 A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF Completed NCT00003199 Phase 2 tamoxifen citrate;busulfan;thiotepa;melphalan
6 A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study Completed NCT00194779 Phase 2 doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
7 An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer Completed NCT01818063 Phase 2 Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
8 A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC) Recruiting NCT02315196 Phase 2 pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
9 Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients Active, not recruiting NCT01372579 Phase 2 eribulin mesylate;carboplatin
10 Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer Active, not recruiting NCT01471106 Phase 2 Dasatinib
11 GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response Terminated NCT01234532 Phase 2 entinostat;anastrozole
12 A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma Terminated NCT01151449 Phase 2 gamma-secretase/Notch signalling pathway inhibitor RO4929097
13 A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer Terminated NCT01918306 Phase 1, Phase 2 cisplatin;GDC -0941
14 Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer Completed NCT00516243 Phase 1 defined green tea catechin extract
15 Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer Completed NCT01104259 Phase 1 veliparib;cisplatin;vinorelbine tartrate
16 Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative Terminated NCT01217411 Phase 1 Gamma-secretase/Notch signalling pathway inhibitor RO4929097
17 A Pilot Study of the Effect of Erlotinib (Tarceva®) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1α Terminated NCT00503841 erlotinib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

MalaCards organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

40
Breast, Bone, Ovary, Lung, Colon, Kidney, Thyroid

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 331)
# Title Authors PMID Year
1
Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer. 61
33810567 2021
2
A Population-Based Study of Genes Previously Implicated in Breast Cancer. 61
33471974 2021
3
Stratification of Estrogen Receptor-Negative Breast Cancer Patients by Integrating the Somatic Mutations and Transcriptomic Data. 61
33613637 2021
4
Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. 61
33230261 2020
5
Uncovering Tumor-Stroma Inter-relationships Using MALDI Mass Spectrometry Imaging. 61
32870688 2020
6
Polycystic ovary syndrome is causally associated with estrogen receptor-positive instead of estrogen receptor-negative breast cancer: a Mendelian randomization study. 61
32413428 2020
7
Coexpression of PBX1 and EMP2 as Prognostic Biomarkers in Estrogen Receptor-Negative Breast Cancer via Data Mining. 61
32216630 2020
8
Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets. 61
32942528 2020
9
GLIS1, a novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A. 61
32047936 2020
10
Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. 61
32878860 2020
11
Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. 61
32471192 2020
12
Development of a nine-lncRNA signature as a novel prognostic marker of estrogen receptor-negative breast cancer. 61
32218854 2020
13
CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. 61
32300202 2020
14
G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer. 61
32034133 2020
15
Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. 61
33194937 2020
16
High expression of soluble CD155 in estrogen receptor-negative breast cancer. 61
31372841 2020
17
Retraction: Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. 61
32218596 2020
18
Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients. 61
32656076 2020
19
Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. 61
32964118 2020
20
Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines. 61
31950839 2020
21
miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. 61
31875548 2019
22
Galbanic acid: Induced antiproliferation in estrogen receptor-negative breast cancer cells and enhanced cellular redox state in the human dermal fibroblasts. 61
31576639 2019
23
GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. 61
31694641 2019
24
Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. 61
31190337 2019
25
β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. 61
31290053 2019
26
Bioinformatics analysis identifies potential chemoresistance-associated genes across multiple types of cancer. 61
31402953 2019
27
Corrigendum to ``Different anticancer effects of Saxifragifolin A on estrogen receptor-positive and estrogen receptor-negative breast cancer cells'' [Phytomedicine 22(9) (2015) 820-828]. 61
31272032 2019
28
AKT-dependent sugar addiction by benzyl isothiocyanate in breast cancer cells. 61
30720225 2019
29
Increased expression of mitochondrial sodium-coupled ascorbic acid transporter-2 (mitSVCT2) as a central feature in breast cancer. 61
30902760 2019
30
Retraction: Sensitizing Estrogen Receptor-negative Breast Cancer Cells to Tamoxifen with OSU-03012, a Novel Celecoxib-derived Phosphoinositide-dependent Protein Kinase-1/Akt Signaling Inhibitor. 61
30936413 2019
31
Oleuropein induces apoptosis via abrogating NF-κB activation cascade in estrogen receptor-negative breast cancer cells. 61
30260018 2019
32
Carvedilol suppresses malignant proliferation of mammary epithelial cells through inhibition of the ROS‑mediated PI3K/AKT signaling pathway. 61
30483797 2019
33
Effect of 17β-estradiol on estrogen receptor negative breast cancer cells in an osteolytic mouse model. 61
29133279 2019
34
Potassium channel activity controls breast cancer metastasis by affecting β-catenin signaling. 61
30792401 2019
35
RASAL2 Plays Inconsistent Roles in Different Cancers. 61
31799194 2019
36
Silencing growth hormone receptor inhibits estrogen receptor negative breast cancer through ATP-binding cassette sub-family G member 2. 61
30617282 2019
37
LRP8 is overexpressed in estrogen-negative breast cancers and a potential target for these tumors. 61
30575334 2019
38
[Effect of serum containing Xihuang pill on proliferation of human breast cancer cell line MDA-MB-435 and MCF-7 Cells]. 61
30111032 2018
39
Analysis of the miRNA-mRNA-lncRNA network in human estrogen receptor-positive and estrogen receptor-negative breast cancer based on TCGA data. 61
29518546 2018
40
Cellular and Animal Model Studies on the Growth Inhibitory Effects of Polyamine Analogues on Breast Cancer. 61
29533973 2018
41
Circadian pathway genetic variation and cancer risk: evidence from genome-wide association studies. 61
29455641 2018
42
The A2B adenosine receptor in MDA-MB-231 breast cancer cells diminishes ERK1/2 phosphorylation by activation of MAPK-phosphatase-1. 61
30157211 2018
43
Associations between Diet Quality Scores and Risk of Postmenopausal Estrogen Receptor-Negative Breast Cancer: A Systematic Review. 61
29378048 2018
44
Transcriptome analysis of genes associated with breast cancer cell motility in response to Artemisinin treatment. 61
29246124 2017
45
Distinct Effects of Body Mass Index and Waist/Hip Ratio on Risk of Breast Cancer by Joint Estrogen and Progestogen Receptor Status: Results from a Case-Control Study in Northern and Eastern China and Implications for Chemoprevention. 61
28912152 2017
46
Identification of ten variants associated with risk of estrogen-receptor-negative breast cancer. 61
29058716 2017
47
Coexpression of NOS2 and COX2 accelerates tumor growth and reduces survival in estrogen receptor-negative breast cancer. 61
29087320 2017
48
Type II Diabetes and Incidence of Estrogen Receptor Negative Breast Cancer in African American Women. 61
29141994 2017
49
Targeting Aberrant p70S6K Activation for Estrogen Receptor-Negative Breast Cancer Prevention. 61
28877935 2017
50
Consequences of the natural retinoid/retinoid X receptor ligands action in human breast cancer MDA-MB-231 cell line: Focus on functional proteomics. 61
28886987 2017

Variations for Estrogen-Receptor Negative Breast Cancer

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Pathways for Estrogen-Receptor Negative Breast Cancer

Pathways related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 83)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.24 VEGFA TGFBR2 SRC PGR IGF1 GPER1
2
Show member pathways
13.84 VEGFA TGFBR2 SRC IGF1 ESR1 ERBB2
3
Show member pathways
13.76 VEGFA TGFBR2 SRC IGF1 ESR1 ERBB2
4
Show member pathways
13.59 VEGFA TGFBR2 SRC IGF1 ERBB2 EGFR
5
Show member pathways
13.35 TGFBR2 SRC IGF1 ERBB2 EGFR EGF
6
Show member pathways
13.31 VEGFA SRC IGF1 ESR1 ERBB2 EGFR
7
Show member pathways
13.02 VEGFA IGF1 ERBB2 EGFR EGF CTNNB1
8
Show member pathways
12.93 VEGFA SRC IGF1 ERBB2 EGFR EGF
9
Show member pathways
12.9 VEGFA TGFBR2 SRC IGF1 EGFR EGF
10 12.81 VEGFA TGFBR2 IGF1 ERBB2 EGFR EGF
11
Show member pathways
12.77 VEGFA SRC IGF1 EGFR EGF CTNNB1
12
Show member pathways
12.71 VEGFA TGFBR2 SRC IGF1 ERBB2 EGFR
13
Show member pathways
12.64 SRC IGF1 GPER1 ESR1 ERBB2 EGFR
14
Show member pathways
12.64 TGFBR2 PGR IGF1 ESR1 ERBB2 EGFR
15 12.57 VEGFA MIR520C ERBB2 EGFR CYP1B1 BRCA1
16
Show member pathways
12.54 VEGFA SRC IGF1 ERBB2 EGFR EGF
17
Show member pathways
12.48 TGFBR2 ERBB2 EGFR CTNNB1
18
Show member pathways
12.46 SRC IGF1 ERBB2 EGFR EGF CTNNB1
19
Show member pathways
12.45 VEGFA SRC ESR1 CTNNB1 BRCA1
20 12.44 VEGFA ORAI3 ERBB2 EGFR EGF
21
Show member pathways
12.4 VEGFA EGFR EGF CTNNB1
22 12.38 VEGFA TGFBR2 IGF1 ESR1 ERBB2 EGFR
23
Show member pathways
12.37 SRC ERBB2 EGFR EGF
24
Show member pathways
12.36 IGF1 ESR1 ERBB2 EGFR EGF
25
Show member pathways
12.36 SRC ERBB2 EGFR EGF CTNNB1
26 12.26 VEGFA SRC IGF1 ESR1 ERBB2 EGFR
27 12.24 SRC ERBB2 EGFR EGF
28 12.24 VEGFA CXCL8 CTNNB1 AR
29 12.23 SRC EGFR EGF CTNNB1
30
Show member pathways
12.19 SRC ERBB2 EGFR EGF
31 12.19 VEGFA TGFBR2 SRC EGFR EGF CTNNB1
32 12.18 SRC ERBB2 EGFR EGF
33
Show member pathways
12.14 TGFBR2 IGF1 EGFR EGF
34 12.13 SRC PGR GPER1 ESR1 EGFR
35 12.12 VEGFA IGF1 FOXA1 EGF
36
Show member pathways
12.08 TGFBR2 SRC IGF1 ERBB2 EGFR EGF
37 12.01 SRC IGF1 EGFR EGF CTNNB1
38 11.99 VEGFA IGF1 ERBB2 EGFR EGF
39
Show member pathways
11.98 PGR ESR1 ERBB2 EGFR EGF
40
Show member pathways
11.92 VEGFA ESR1 ERBB2 EGFR
41
Show member pathways
11.91 SRC EGFR EGF CTNNB1
42 11.88 SRC EGFR EGF
43 11.87 SRC EGFR CTNNB1 BRCA1 AR
44 11.83 CXCL8 CTNNB1 AR
45 11.83 VEGFA IGF1 EGF
46
Show member pathways
11.82 SRC EGFR EGF
47
Show member pathways
11.77 VEGFA ESR1 EGFR
48 11.76 SRC ERBB2 EGFR CTNNB1
49 11.75 ESR1 EGFR EGF
50 11.74 SRC EGFR CXCL8

GO Terms for Estrogen-Receptor Negative Breast Cancer

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 platelet alpha granule lumen GO:0031093 8.8 VEGFA IGF1 EGF

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 59)
# Name GO ID Score Top Affiliating Genes
1 signal transduction GO:0007165 10.31 VEGFA SRC PGR IGF1 GPER1 ESR1
2 regulation of transcription by RNA polymerase II GO:0006357 10.29 VEGFA PGR FOXA1 ESR1 ERBB2 EGFR
3 cell differentiation GO:0030154 10.22 VEGFA TGFBR2 SRC GPER1 FOXA1 EGFR
4 positive regulation of transcription by RNA polymerase II GO:0045944 10.16 VEGFA PGR IGF1 GPER1 FOXA1 ESR1
5 positive regulation of apoptotic process GO:0043065 10.09 SRC GPER1 FOXA1 CYP1B1 CTNNB1
6 negative regulation of cell proliferation GO:0008285 10.09 TGFBR2 GPER1 CYP1B1 CXCL8 CTNNB1 AR
7 positive regulation of transcription, DNA-templated GO:0045893 10.09 TP53INP2 SRC IGF1 ESR1 EGFR EGF
8 regulation of gene expression GO:0010468 10.07 TGFBR2 IGF1 FOXA1 CTNNB1 AR
9 positive regulation of cell migration GO:0030335 10.03 VEGFA IGF1 GPER1 EGFR EGF
10 angiogenesis GO:0001525 10.02 VEGFA EGF CYP1B1 CXCL8
11 positive regulation of ERK1 and ERK2 cascade GO:0070374 10.01 VEGFA SRC GPER1 EGFR
12 in utero embryonic development GO:0001701 10.01 VEGFA TGFBR2 CTNNB1 AR
13 regulation of cell proliferation GO:0042127 10.01 TGFBR2 SRC CTNNB1 BRCA1
14 positive regulation of protein phosphorylation GO:0001934 10.01 VEGFA GPER1 ERBB2 EGFR
15 positive regulation of angiogenesis GO:0045766 9.97 VEGFA TGFBR2 CYP1B1 CXCL8 BRCA1
16 peptidyl-tyrosine phosphorylation GO:0018108 9.96 SRC ERBB2 EGFR EGF
17 response to estradiol GO:0032355 9.96 FOXA1 ESR1 EGFR CYP19A1 CTNNB1
18 positive regulation of protein kinase B signaling GO:0051897 9.95 VEGFA SRC ESR1 ERBB2 EGFR EGF
19 wound healing GO:0042060 9.92 TGFBR2 IGF1 ERBB2 EGFR
20 lung development GO:0030324 9.92 VEGFA TGFBR2 FOXA1 EGFR CTNNB1
21 positive regulation of peptidyl-tyrosine phosphorylation GO:0050731 9.91 VEGFA SRC IGF1 EGF
22 positive regulation of cell proliferation GO:0008284 9.91 VEGFA TGFBR2 IGF1 GPER1 ERBB2 EGFR
23 cellular response to growth factor stimulus GO:0071363 9.89 TGFBR2 ERBB2 EGFR CTNNB1
24 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.89 VEGFA SRC IGF1 GPER1 EGF
25 vasculogenesis GO:0001570 9.88 VEGFA TGFBR2 CTNNB1
26 response to estrogen GO:0043627 9.88 TGFBR2 ESR1 BRCA1
27 positive regulation of epithelial cell proliferation GO:0050679 9.88 VEGFA IGF1 ERBB2 EGFR
28 positive regulation of smooth muscle cell proliferation GO:0048661 9.87 TGFBR2 IGF1 EGFR
29 positive regulation of cell adhesion GO:0045785 9.87 VEGFA SRC ERBB2
30 epidermal growth factor receptor signaling pathway GO:0007173 9.86 SRC EGFR EGF
31 negative regulation of extrinsic apoptotic signaling pathway GO:2001237 9.84 SRC IGF1 AR
32 positive regulation of phosphorylation GO:0042327 9.84 VEGFA EGFR EGF AR
33 cellular response to estradiol stimulus GO:0071392 9.83 GPER1 ESR1 EGFR
34 regulation of cell motility GO:2000145 9.82 ERBB2 EGFR EGF
35 branching involved in blood vessel morphogenesis GO:0001569 9.81 VEGFA TGFBR2 CTNNB1
36 ERBB2 signaling pathway GO:0038128 9.81 SRC ERBB2 EGFR EGF
37 positive regulation of MAP kinase activity GO:0043406 9.8 VEGFA SRC ERBB2 EGFR EGF
38 steroid hormone mediated signaling pathway GO:0043401 9.79 PGR GPER1 ESR1
39 positive regulation of mesenchymal cell proliferation GO:0002053 9.77 VEGFA TGFBR2 CTNNB1
40 negative regulation of gene expression GO:0010629 9.76 VEGFA PGR MIR520C IGF1 GPER1 ESR1
41 cellular process GO:0009987 9.73 CTNNB1 AR
42 regulation of protein localization to cell surface GO:2000008 9.72 EGF CTNNB1
43 positive regulation of protein localization to early endosome GO:1902966 9.72 VEGFA EGF
44 regulation of calcium ion import GO:0090279 9.72 EGF CTNNB1
45 progesterone receptor signaling pathway GO:0050847 9.72 SRC PGR
46 negative regulation of ERBB signaling pathway GO:1901185 9.72 ERBB2 EGFR EGF
47 entry of bacterium into host cell GO:0035635 9.71 SRC CTNNB1
48 prostate gland epithelium morphogenesis GO:0060740 9.7 FOXA1 AR
49 trachea formation GO:0060440 9.69 TGFBR2 CTNNB1
50 cellular response to indole-3-methanol GO:0071681 9.68 CTNNB1 BRCA1

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 chromatin binding GO:0003682 9.8 GPER1 FOXA1 ESR1 EGFR CTNNB1 AR
2 enzyme binding GO:0019899 9.7 SRC PGR ESR1 EGFR CTNNB1 BRCA1
3 beta-catenin binding GO:0008013 9.67 ESR1 CTNNB1 AR
4 nuclear receptor activity GO:0004879 9.61 PGR ESR1 AR
5 estrogen receptor binding GO:0030331 9.54 SRC ESR1 CTNNB1
6 nitric-oxide synthase regulator activity GO:0030235 9.48 ESR1 EGFR
7 RNA polymerase II transcription coactivator binding GO:0001225 9.46 PGR AR
8 steroid hormone receptor activity GO:0003707 9.43 PGR GPER1 ESR1
9 estrogen receptor activity GO:0030284 9.4 GPER1 ESR1
10 steroid binding GO:0005496 9.26 PGR GPER1 ESR1 AR
11 ATPase binding GO:0051117 9.02 SRC PGR ESR1 EGFR AR

Sources for Estrogen-Receptor Negative Breast Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 20-May-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....